{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:21Z","timestamp":1792783161277,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","id":[{"id":"https:\/\/ror.org\/041nas322","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Blood group O has recently been associated with improved survival in patients with MGMT-methylated glioblastoma. However, whether this association persists in patients treated with intensified first-line radiochemotherapy according to the CeTeG\/NOA-09 regimen remains unclear. We aimed to validate the prognostic impact of ABO blood group in an independent cohort of patients with MGMT-methylated, IDH-wildtype glioblastoma uniformly treated with CCNU\/temozolomide (CCNU\/TMZ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective single-center cohort study including adult patients with newly diagnosed MGMT-methylated, IDH-wildtype glioblastoma treated according to the CeTeG\/NOA-09 protocol between 2008 and 2023. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan\u2013Meier estimates, log-rank tests, and multivariable Cox proportional hazards models adjusted for age, extent of resection, and Karnofsky Performance Status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-one patients were included, of whom 24 (39.3%) had blood group O and 37 (60.7%) had non-O blood groups. Blood group O was associated with longer OS (median 42.1 vs. 23.7 months; log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and a trend toward longer PFS (median 21.8 vs. 17.5 months; log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.10). After multivariable adjustment, non-O blood groups remained independently associated with shorter PFS (HR 1.86, 95% CI 1.04\u20133.34;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037) and OS (HR 2.29, 95% CI 1.16\u20134.52;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Blood group O remained associated with improved progression-free and overall survival in patients with MGMT-methylated, IDH-wildtype glioblastoma treated according to the CeTeG\/NOA-09 regimen. These findings support an association between blood group O and improved survival outcomes and warrant further investigation of its biological and clinical relevance in glioblastoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05813-y","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:49:18Z","timestamp":1790250558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine"],"prefix":"10.1007","volume":"179","author":[{"given":"Julia","family":"Scheuble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Laura","family":"Potthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Lex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea L.","family":"Friker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Radbruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P.","family":"Layer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Vatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"5813_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn J-C, Tsang J, Verhaak RGW, Von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, Van Den Bent MJ (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncol 22:1073\u20131113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106","journal-title":"Neuro-Oncol"},{"key":"5813_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/neuonc\/noae231","volume":"27","author":"P Karschnia","year":"2025","unstructured":"Karschnia P, Young JS, Youssef GC, Dono A, H\u00e4ni L, Sciortino T, Bruno F, Juenger ST, Teske N, Dietrich J, Weller M, Vogelbaum MA, van den Bent M, Beck J, Thon N, Gerritsen JKW, Hervey-Jumper S, Cahill DP, Chang SM, Rud\u00e0 R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Huang RY, Wen PY, Berger MS, Molinaro AM, Tonn J-C (2025) Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect group. Neuro-Oncol 27:1046\u20131060. https:\/\/doi.org\/10.1093\/neuonc\/noae231","journal-title":"Neuro-Oncol"},{"key":"5813_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ijc.34533","volume":"153","author":"H Cui","year":"2023","unstructured":"Cui H, Qu Y, Zhang L, Zhang W, Yan P, Yang C, Zhang M, Bai Y, Tang M, Wang Y, Chen L, Xiao C, Zou Y, Liu Y, Zhang L, Yang Y, Yao Y, Li J, Liu Z, Yang C, Jiang X, Zhang B (2023) Epidemiological and genetic evidence for the relationship between ABO blood group and human cancer. Int J Cancer 153:320\u2013330. https:\/\/doi.org\/10.1002\/ijc.34533","journal-title":"Int J Cancer"},{"key":"5813_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/02688697.2018.1522415","volume":"33","author":"A Alkan","year":"2019","unstructured":"Alkan A, Yaz\u0131c\u0131 G, Cengiz M, Karaka\u015f Y, \u00c7elik \u0130, Kars A, Zorlu F (2019) The role of ABO blood groups in glial neoplasms. Br J Neurosurg 33:43\u201346. https:\/\/doi.org\/10.1080\/02688697.2018.1522415","journal-title":"Br J Neurosurg"},{"key":"5813_CR5","volume-title":"Central nervous system tumours","author":"Organisation mondiale de la sant\u00e9, Centre international de recherche sur le cancer","year":"2021","unstructured":"Organisation mondiale de la sant\u00e9, Centre international de recherche sur le cancer (2021) Central nervous system tumours, 5th edn. International agency for research on cancer, Lyon","edition":"5"},{"key":"5813_CR6","doi-asserted-by":"publisher","first-page":"vdaf037","DOI":"10.1093\/noajnl\/vdaf037","volume":"7","author":"R Wiewrodt","year":"2025","unstructured":"Wiewrodt R, Kloss M, Jost-Engl J, Troschel FM, Troschel BO, Eich HT, Thomas C, Lemcke L, Stummer W, Wiewrodt D (2025) Blood group O attributes to prolonged progression-free survival, overall survival, and 5-year survival in isocitrate dehydrogenase-wildtype glioblastoma patients with MGMT promoter methylation. Neuro-Oncol Adv 7:vdaf037. https:\/\/doi.org\/10.1093\/noajnl\/vdaf037","journal-title":"Neuro-Oncol Adv"},{"key":"5813_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann R-D, Krex D, Grauer O, Goldbrunner R, Schnell O, B\u00e4hr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Sch\u00e4fer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn J-C, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA\u201309): a randomised, open-label, phase 3 trial. Lancet 393:678\u2013688. https:\/\/doi.org\/10.1016\/S0140-6736(18)31791-4","journal-title":"Lancet"},{"key":"5813_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2353\/jmoldx.2007.060167","volume":"9","author":"T Mikeska","year":"2007","unstructured":"Mikeska T, Bock C, El-Maarri O, H\u00fcbner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, B\u00fcttner R, Pietsch T, Waha A (2007) Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. J Mol Diagn 9:368\u2013381. https:\/\/doi.org\/10.2353\/jmoldx.2007.060167","journal-title":"J Mol Diagn"},{"key":"5813_CR9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, Van Den Bent MJ, Chang SM (2010) Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963\u20131972. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541","journal-title":"J Clin Oncol"},{"key":"5813_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000339235","volume":"39","author":"P Bugert","year":"2012","unstructured":"Bugert P, Rink G, Kemp K, Kl\u00fcter H (2012) Blood Group ABO Genotyping in Paternity Testing. Transfus Med Hemotherapy 39:182\u2013186. https:\/\/doi.org\/10.1159\/000339235","journal-title":"Transfus Med Hemotherapy"},{"key":"5813_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/glycob\/10.4.375","volume":"10","author":"C Goupille","year":"2000","unstructured":"Goupille C, Marionneau S, Bureau V, Hallouin F, Meichenin M, Rocher J, Le Pendu J (2000) 1,2Fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells. Glycobiology 10:375\u2013382. https:\/\/doi.org\/10.1093\/glycob\/10.4.375","journal-title":"Glycobiology"},{"key":"5813_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41420-019-0145-y","volume":"5","author":"T-Y Lai","year":"2019","unstructured":"Lai T-Y, Chen I-J, Lin R-J, Liao G-S, Yeo H-L, Ho C-L, Wu J-C, Chang N-C, Lee AC-L, Yu AL (2019) Fucosyltransferase 1 and 2 play pivotal roles in breast cancer cells. Cell Death Discov 5:74. https:\/\/doi.org\/10.1038\/s41420-019-0145-y","journal-title":"Cell Death Discov"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05813-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:01:45Z","timestamp":1792087305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05813-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5813"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05813-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective analysis was approved by the Ethics Committee of the University Hospital Bonn (reference no. 09\/22) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was waived in accordance with local and national legislation.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JPL reports stocks and travel expenses from TME Pharma AG; travel expenses and honoraria from Carl Zeiss Meditec AG and Biotex Inc., stocks and honoraria from Siemens Healthineers AG, and stocks from Bayer AG and BioNTech AG. UH reports advisory board and\/or speakers honoraria from Medac, Servier, OncomagentX, Bayer. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"101"}}